Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
Status:
Withdrawn
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Ketamine infusions resulted in an acute reduction in global depression scores and in severity
of suicidal ideation. Scopolamine infusions produced also a significant improvement in
depression that was sustained over time.
We therefore plan to investigate the feasibility and efficacy of open-label repeated
intravenous administration of ketamine and scopolamine combined in this population of
severely depressed, treatment-resistant patients. The results from this study could lead to
the development of new strategies for the treatment of patients with TRD.